Pharma BD Deal Intelligence

Neurocrine Biosciences Inc. / Takeda Pharmaceutical Company Ltd.

2025 · Licensing/Option · Complete

Neurocrine Biosciences and Takeda entered an Amended and Restated Exclusive License Agreement that amends and restates in its entirety their Exclusive License Agreement of June 12, 2020. The restructuring converts osavampator (NBI-1065845 / TAK-653) from an operating profit-and-loss share to a royalty-bearing license, returns Japanese rights to Takeda, and reflects Neurocrine's prior termination of the DAAO inhibitor programs (including luvadaxistat) and GPR139 agonists (including NBI-1065846). Neurocrine retains exclusive worldwide rights to develop and commercialize osavampator, a potential first-in-class AMPA positive allosteric modulator in development for major depressive disorder with inadequate treatment response, in all territories except Japan. Each party funds development in its own territory, each is eligible for royalties on the other's net sales, and Takeda is eligible for development and commercial milestones.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals  ·  Neurocrine Biosciences Inc. deals  ·  Neurology deals